169 related articles for article (PubMed ID: 30683515)
1. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
Ausania F; Senra Del Rio P; Gomez-Bravo MA; Martin-Perez E; Pérez-Daga JA; Dorcaratto D; González-Nicolás T; Sanchez-Cabus S; Tardio-Baiges A
Pancreatology; 2019 Mar; 19(2):367-371. PubMed ID: 30683515
[TBL] [Abstract][Full Text] [Related]
2. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
3. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
5. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
6. Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours.
Ricci C; Casadei R; Taffurelli G; Campana D; Ambrosini V; Pagano N; Santini D; De Giorgio R; Ingaldi C; Tomassetti P; Zani E; Minni F
Pancreatology; 2016; 16(3):403-10. PubMed ID: 26924664
[TBL] [Abstract][Full Text] [Related]
7. Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study.
Zou S; Jiang Y; Wang W; Zhan Q; Deng X; Shen B
Int J Surg; 2020 Feb; 74():86-91. PubMed ID: 31926324
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
[TBL] [Abstract][Full Text] [Related]
9. Outcome of surgery for pancreatic neuroendocrine neoplasms.
Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
[TBL] [Abstract][Full Text] [Related]
10. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
[TBL] [Abstract][Full Text] [Related]
11. Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis.
Lindner K; Binte D; Hoeppner J; Wellner UF; Schulte DM; Schmid SM; Luley K; Buchmann I; Tharun L; Keck T; Gebauer J; Kulemann B
Curr Oncol; 2021 Aug; 28(4):3071-3080. PubMed ID: 34436034
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors after resection of locally advanced non-functional pancreatic neuroendocrine neoplasm: an analysis from the German Cancer Registry Group of the Society of German Tumor Centers.
Abdalla TSA; Klinkhammer-Schalke M; Zeissig SR; Tol KK; Honselmann KC; Braun R; Bolm L; Lapshyn H; Litkevych S; Zemskov S; Begum N; Kulemann B; Hummel R; Wellner UF; Keck T; Deichmann S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8535-8543. PubMed ID: 37095413
[TBL] [Abstract][Full Text] [Related]
13. Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreas; 2019 Aug; 48(7):943-947. PubMed ID: 31268980
[TBL] [Abstract][Full Text] [Related]
14. Major postoperative complications after pancreatic resection for P-NETS are not associated to earlier recurrence.
Valente R; Lykoudis P; Tamburrino D; Inama M; Passas I; Toumpanakis C; Luong TV; Davidson B; Imber C; Malagò M; Rahman SH; Shankar A; Sharma D; Caplin M; Fusai G
Eur J Surg Oncol; 2017 Nov; 43(11):2119-2128. PubMed ID: 28821361
[TBL] [Abstract][Full Text] [Related]
15. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
[TBL] [Abstract][Full Text] [Related]
16. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
[TBL] [Abstract][Full Text] [Related]
17. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies.
Watzka FM; Meyer F; Staubitz JI; Fottner C; Schad A; Lang H; Musholt TJ
World J Surg; 2020 Feb; 44(2):594-603. PubMed ID: 31605171
[TBL] [Abstract][Full Text] [Related]
19. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors.
Pulvirenti A; Javed AA; Landoni L; Jamieson NB; Chou JF; Miotto M; He J; Gonen M; Pea A; Tang LH; Nessi C; Cingarlini S; D'Angelica MI; Gill AJ; Kingham TP; Scarpa A; Weiss MJ; Balachandran VP; Samra JS; Cameron JL; Jarnagin WR; Salvia R; Wolfgang CL; Allen PJ; Bassiy C
Ann Surg; 2021 Dec; 274(6):1051-1057. PubMed ID: 31567347
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index.
Weynand B; Borbath I; Bernard V; Sempoux C; Gigot JF; Hubert C; Lannoy V; Deprez PH; Jouret-Mourin A
Cytopathology; 2014 Dec; 25(6):389-95. PubMed ID: 24750272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
